Evaxion Biotech A/S

Evaxion Biotech A/S Stock Forecast & Price Prediction

Live Evaxion Biotech A/S Stock (EVAX) Price
$2.42

0

Ratings

  • Buy 0
  • Hold 0
  • Sell 0
Disclaimer : Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance. This information is for educational purposes only and should not be construed as advice to buy or sell any security.

Stock Price

$2.42

P/E Ratio

-0.28

Volume Traded Today

$28,819

Dividend

Dividends not available for EVAX

52 Week High/low

13.61/2.26

Evaxion Biotech A/S Market Cap

$13.3M

๐Ÿ›‘ Alert: These ten stocks could have higher potential than $EVAX ๐Ÿ›‘

Before you buy EVAX you'll want to see this list of ten stocks that have huge potential. Want to see if EVAX made the cut? Enter your email below

EVAX Summary

Based on ratings from 0 stock analysts, the Evaxion Biotech A/S stock price is expected to increase by 348.35% in 12 months. This is calculated by using the average 12-month stock price forecast for Evaxion Biotech A/S. The lowest target is $7 and the highest is $18. Please note analyst price targets are not guaranteed and could be missed completely.

EVAX Analyst Ratings

About 0 Wall Street analysts have assignedEVAX 0 buy ratings, 0 hold ratings, and 0 sell ratings. This means that analysts expect Evaxion Biotech A/S to sell. Keep in mind that these ratings are typically refreshed every quarter, underscoring the importance of conducting your own research on EVAX. Don't forget to include both technical and fundamental analysis, as well as staying informed on news that could influence these ratings, in your due diligence.

EVAX stock forecast by analyst

These are the latest 20 analyst ratings of EVAX.

Analyst/Firm

Rating

Price Target

Change

Date

Swayampakula Ramakanth
HC Wainwright & Co.

Buy

$14

Reiterates

Nov 1, 2024
Swayampakula Ramakanth
HC Wainwright & Co.

Buy

$14

Reiterates

Sep 26, 2024
Swayampakula Ramakanth
HC Wainwright & Co.

Buy

$14

Reiterates

Sep 20, 2024
Swayampakula Ramakanth
HC Wainwright & Co.

Buy

$14

Reiterates

Aug 16, 2024
Swayampakula Ramakanth
HC Wainwright & Co.

Buy

$14

Reiterates

Aug 1, 2024
Swayampakula Ramakanth
HC Wainwright & Co.

Buy

$14

Reiterates

Jun 4, 2024
Swayampakula Ramakanth
HC Wainwright & Co.

Buy

$14

Reiterates

Apr 3, 2024
Ahu Demir
Ladenburg Thalmann

Buy

$8

Upgrade

Apr 2, 2024
Swayampakula Ramakanth
HC Wainwright & Co.

Buy

$14

Reiterates

Mar 20, 2024
Swayampakula Ramakanth
HC Wainwright & Co.

Buy

$14

Initiates

Feb 12, 2024
Ahu Demir
Ladenburg Thalmann

Neutral


Downgrade

Dec 21, 2023
Thomas Flaten
Lake Street

Buy

$7

Maintains

Mar 31, 2023
Jeff Jones
Oppenheimer

Outperform

$11

Maintains

Nov 17, 2022
Jeff Jones
Oppenheimer

Outperform

$16

Assumes

Jul 18, 2022
Kevin DeGeeter
Oppenheimer

Outperform

$18

Initiates

Mar 2, 2021

EVAX Company Information

What They Do: Develops AI-powered immunotherapies and vaccines.

Business Model: Evaxion Biotech A/S focuses on developing innovative immunotherapies and vaccines using artificial intelligence. The company generates revenue through clinical trials and potential future sales of its therapeutic products, including DNA-based vaccines currently in various stages of clinical trials aimed at treating cancers and preventing infections.

Other Information: Founded in 2008 and headquartered in Horsholm, Denmark, Evaxion Biotech is in the clinical stage of its development, with multiple product candidates targeting serious health conditions. The company is actively pursuing advancements in immunotherapy to address unmet medical needs in oncology and infectious diseases.
EVAX
Evaxion Biotech A/S (EVAX)

When did it IPO

2020

Staff Count

49

Country

Denmark

Sector/Industry

Healthcare/Biotechnology

CEO

Market Cap

$13.3M

Evaxion Biotech A/S (EVAX) Financial Data

In 2023, EVAX generated $73,000 in revenue, which was a increase of 0.00% from the previous year. This can be seen as a signal that EVAX's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.

Revenue From 2020

$0

Revenue From 2021

$0

0.00 %
From Previous Year

Revenue From 2022

$0

0.00 %
From Previous Year

Revenue From 2023

$73,000

0.00 %
From Previous Year
  • Revenue TTM $3.3M
  • Operating Margin TTM -57.4%
  • Gross profit TTM $0
  • Return on assets TTM -69.5%
  • Return on equity TTM 466.9%
  • Profit Margin 0.0%
  • Book Value Per Share 0.01%
  • Market capitalisation $13.3M
  • Revenue for 2021 $0
  • Revenue for 2022 $0
  • Revenue for 2023 $73,000
  • EPS this year (TTM) $-2.80

Evaxion Biotech A/S (EVAX) Latest News

News Image

Tue, 12 Nov 2024

Sentiment - NEUTRAL

Source - GlobeNewsWire

Summary - Evaxion Biotech (NASDAQ: EVAX) reported positive preclinical data for its CMV vaccine EVX-V1, to be presented at the 9th International Conference on Vaccines Research & Development in Boston.

Why It Matters - Positive preclinical data for Evaxion's CMV vaccine can boost investor confidence, potentially increasing stock value and signaling progress in the biotech sector.

News Image

Thu, 31 Oct 2024

Sentiment - NEUTRAL

Source - GlobeNewsWire

Summary - Evaxion Biotech A/S (NASDAQ: EVAX) announced its Q3 2024 financial results and provided a business update on its AI-Immunologyโ„ข powered vaccine developments.

Why It Matters - Evaxion's update and Q3 financial results signal its progress in AI-driven vaccine development, impacting investor confidence and potential future valuation.

News Image

Mon, 28 Oct 2024

Sentiment - NEUTRAL

Source - GlobeNewsWire

Summary - Evaxion Biotech A/S (NASDAQ: EVAX) will release its third quarter 2024 financial results and business update on October 31, 2024, before market opening.

Why It Matters - Evaxion's upcoming Q3 financial results and business update could impact its stock price, reflecting performance and strategic direction in the AI-vaccine sector.

News Image

Wed, 09 Oct 2024

Sentiment - NEUTRAL

Source - GlobeNewsWire

Summary - Evaxion Biotech (NASDAQ: EVAX) reported validation of its AI-Immunologyโ„ข vaccine target predictions from three clinical trials, enhancing its position in the biotech sector.

Why It Matters - Successful validation of AI-driven vaccine targets enhances Evaxion's credibility, potentially leading to increased investor confidence and market interest in its innovative technology and future products.

News Image

Thu, 03 Oct 2024

Sentiment - NEUTRAL

Source - GlobeNewsWire

Summary - Evaxion Biotech A/S (NASDAQ: EVAX) is advancing its AI-Immunologyโ„ข platform, focusing on clinical evidence to enhance its vaccine development.

Why It Matters - Evaxion's advancements in its AI-Immunologyโ„ข platform could enhance vaccine efficacy, driving potential market growth and investor interest in its future clinical successes.

News Image

Thu, 26 Sep 2024

Sentiment - NEUTRAL

Source - GlobeNewsWire

Summary - Evaxion Biotech A/S has signed an option and license agreement with Merck for two preclinical vaccine candidates, enhancing their collaboration and adding significant value to Evaxion.

Why It Matters - The agreement with Merck enhances Evaxion's pipeline and potential revenue, signaling confidence in its AI-driven vaccine technology, which may attract investor interest and boost stock performance.

...

EVAX Frequently asked questions

The highest forecasted price for EVAX is $18 from Kevin DeGeeter at Oppenheimer.

The lowest forecasted price for EVAX is $7 from Thomas Flaten from Lake Street

The EVAX analyst ratings consensus are 0 buy ratings, 0 hold ratings, and 0 sell ratings.